Shares of Prothena Corp. (NASDAQ:PRTA) fell 2% on Tuesday . The stock traded as low as $53.02 and last traded at $53.25, with a volume of 287,851 shares. The stock had previously closed at $54.34.

Several research firms recently weighed in on PRTA. Barclays PLC lifted their price target on Prothena Corp. from $60.00 to $70.00 and gave the stock an “overweight” rating in a report on Thursday, August 4th. Wedbush reissued an “outperform” rating and set a $77.00 price target on shares of Prothena Corp. in a report on Wednesday, August 3rd. Royal Bank Of Canada reissued an “outperform” rating and set a $95.00 price target on shares of Prothena Corp. in a report on Monday, July 18th. Credit Suisse Group AG reissued a “buy” rating on shares of Prothena Corp. in a report on Tuesday, July 12th. Finally, Zacks Investment Research raised Prothena Corp. from a “sell” rating to a “hold” rating in a report on Friday, May 6th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $76.60.

The company’s market cap is $1.86 billion. The company has a 50-day moving average price of $52.23 and a 200-day moving average price of $43.59.

Prothena Corp. (NASDAQ:PRTA) last issued its quarterly earnings data on Tuesday, August 2nd. The company reported ($1.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.91) by $0.27. The business earned $0.33 million during the quarter, compared to analysts’ expectations of $0.39 million. Prothena Corp.’s revenue for the quarter was up 22.2% compared to the same quarter last year. Equities research analysts forecast that Prothena Corp. will post ($4.25) earnings per share for the current year.

In other news, insider Arthur W. Homan sold 9,375 shares of the company’s stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $52.14, for a total value of $488,812.50. Following the completion of the transaction, the insider now directly owns 9,375 shares of the company’s stock, valued at $488,812.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Several institutional investors have added to or reduced their stakes in PRTA. New York State Common Retirement Fund raised its position in Prothena Corp. by 4.0% in the fourth quarter. New York State Common Retirement Fund now owns 31,000 shares of the company’s stock valued at $2,111,000 after buying an additional 1,200 shares in the last quarter. Wells Fargo & Company MN raised its position in Prothena Corp. by 2,138.8% in the fourth quarter. Wells Fargo & Company MN now owns 245,639 shares of the company’s stock valued at $16,730,000 after buying an additional 234,667 shares in the last quarter. Finally, Jennison Associates LLC raised its position in Prothena Corp. by 0.5% in the fourth quarter. Jennison Associates LLC now owns 406,677 shares of the company’s stock valued at $27,699,000 after buying an additional 1,912 shares in the last quarter.

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.